罗米司亭治疗化疗所致血小板减少症
该II期随机试验在实体瘤化疗所致血小板减少症(CIT)患者中比较罗米司亭与观察,随机阶段罗米司亭组15例中14例(93%)在3周内血小板计数纠正,对照组8例中仅1例(12.5%,P < .001)。全部52例罗米司亭治疗患者治疗2周时平均血小板计数为141,000/μL,多数患者得以恢复化疗且CIT复发少见。
要点
- 罗米司亭可纠正CIT:随机阶段93%对12.5%(P < .001)
- 治疗2周平均血小板计数升至141,000/μL
核心结论
- 罗米司亭可有效纠正化疗所致血小板减少症,维持治疗使多数患者能够恢复化疗而不出现CIT复发。
研究设计与样本
- II期随机试验,比较罗米司亭与不予治疗的观察,研究对象为伴CIT的实体瘤患者。
- 入组前患者血小板低于100,000/μL持续至少4周,且已因CIT延迟或减量化疗。
- 罗米司亭每周滴定给药,目标血小板计数为100,000/μL或以上;对照组接受常规监测。
- 主要终点为3周内血小板计数纠正;恢复化疗且CIT不复发为次要终点。
主要发现
- 入组时平均血小板计数为62,000/μL。
- 随机阶段罗米司亭组15例中14例(93%)在3周内血小板计数纠正,对照组8例中1例(12.5%;P < .001)。
- 全部罗米司亭治疗患者(N = 52)治疗2周时平均血小板计数为141,000/μL。
- 8例观察患者3周时平均血小板计数为57,000/μL。
关键数值与推荐
- 主要终点为3周内血小板计数纠正。
- 罗米司亭每周滴定,目标血小板计数100,000/μL或以上。
- 入组标准为血小板低于100,000/μL持续至少4周,且已因CIT延迟或减量化疗。
临床怎么用
- 对实体瘤CIT患者可考虑罗米司亭每周滴定至血小板100,000/μL以上以纠正血小板减少。
- 血小板纠正后可每周维持罗米司亭并恢复化疗,多数患者不因单纯CIT再次减量或延迟。
局限性
- 随机阶段样本量小(罗米司亭组15例、对照组8例)。
- 另37例为单臂罗米司亭阶段,非随机对照。
- 随访与安全性数据在摘要中未详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment. METHODS: We conducted a phase II randomized trial of romiplostim versus untreated observation in patients with solid tumors with CIT. Before enrollment, patients had platelets less than 100,000/μL for at least 4 weeks, despite delay or dose reduction of chemotherapy. Patients received weekly titrated romiplostim with a target platelet count of 100,000/μL or more, or were monitored with usual care. The primary end point was correction of platelet count within 3 weeks. Twenty-three patients were treated in a randomization phase, and an additional 37 patients were treated in a single-arm, romiplostim phase. Resumption of chemotherapy without recurrent CIT was a secondary end point. RESULTS: The mean platelet count at enrollment was 62,000/μL. In the randomization phase, 14 of 15 romiplostim-treated patients (93%) experienced correction of their platelet count within 3 weeks, compared with one of eight control patients (12.5%; P < .001). Including all romiplostim-treated patients (N = 52), the mean platelet count at 2 weeks of treatment was 141,000/μL. The mean platelet count in the eight observation patients at 3 weeks was 57,000/μL. Forty-four patients who achieved platelet correction with romiplostim resumed chemotherapy with weekly romiplostim. Only three patients (6.8%) experienced recurrent reduction or delay of chemotherapy because of isolated CIT. CONCLUSION: This prospective trial evaluated treatment of CIT with romiplostim. Romiplostim is effective in correcting CIT, and maintenance allows for resumption of chemotherapy without recurrence of CIT in most patients.
引用
- Soff GA, Miao Y, Bendheim G, et al. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. J Clin Oncol. 2019. PMID: 31545663. doi:10.1200/JCO.18.01931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。